LSN2839567

CAS No. 1231930-57-6

LSN2839567( —— )

Catalog No. M32766 CAS No. 1231930-57-6

LSN2839567 (Abemaciclib metabolite M2) is the active metabolite of Abemaciclib, a potent CDK4 and CDK6 inhibitor (IC50s: 1-3 nM) with anticancer activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 117 In Stock
10MG 188 In Stock
25MG 417 In Stock
50MG 601 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    LSN2839567
  • Note
    Research use only, not for human use.
  • Brief Description
    LSN2839567 (Abemaciclib metabolite M2) is the active metabolite of Abemaciclib, a potent CDK4 and CDK6 inhibitor (IC50s: 1-3 nM) with anticancer activity.
  • Description
    Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s of 1.2 and 1.3 nM, respectively. Anti-cancer activity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1231930-57-6
  • Formula Weight
    478.54
  • Molecular Formula
    C25H28F2N8
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 2 mg/mL (4.18 mM; Ultrasonic )
  • SMILES
    CC(C)n1c(C)nc2c(F)cc(cc12)-c1nc(Nc2ccc(CN3CCNCC3)cn2)ncc1F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Teresa Burke, et al. Abstract 2830: The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6. Cancer Research. July 2016, 76 (14).
molnova catalog
related products
  • CYC065

    CYC065 is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9.

  • CDK9-IN-15

    CDK9-IN-15 is a potent small molecule CDK9 inhibitor, which can block the phosphorylation of positive transcription elongation factor b (P-TEFb) on the C-terminal region of RNA Poly-II by degradation and inhibition of CDK9, inhibit transcription, and rapidly reduce the level of intracellular mRNA, thereby causing apoptosis of tumor cells.

  • Indisulam

    Indisulam (E7070) is potent, sulfonamide, cell-cycle inhibitor that possesses antiproliferative activities, causes decrease in the S phase fraction along with G1 and/or G2 accumulation in various cancer cell lines.